Ionis Pharmaceuticals
Update in progressIONS (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Ionis Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on RNA-targeted medicines in the United States. Its approved therapies include SPINRAZA for spinal muscular atrophy, WAYLIVRA for familial chylomicronemia and partial lipodystrophy, TEGSEDI for hereditary transthyretin–mediated polyneuropathy, QALSODY for ALS, DAWNZERA for hereditary angioedema, TRYNGOLZA for FCS, and WAINUA for ATTRv-PN. It also pursues Olezarsen, Zilganerse, ION582, Eplontersen, Pelacarsen, and other programs, with multiple collaborations (Biogen, GSK, AstraZeneca, Novartis, Roche, Metagenomi). Based in Carlsbad, CA, since 1989.
Company score
- Sentiment
- 0.19
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.80
- Governance
- 0.15
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.27
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.23
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
No news articles are available for this company yet.
Unable to load company news.
You're all caught up!